ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01199367
Recruitment Status : Terminated (The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.)
First Posted : September 10, 2010
Last Update Posted : April 7, 2014
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2012
  Actual Study Completion Date : December 2012
Publications of Results:
Dickson MA, P. LoRusso P, E. A. Sausville EA, Rao N, Kobayashi E, Kurman MR, Akinaga S, Schwartz GK. Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3078)